Rise of GLP-1s raises long-term affordability questions

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. ...

Why weight‑loss drugs don't work for some people

Weight-loss jabs are the latest craze for shedding a few pounds. Their effect has been dramatic, with drugs such as Ozempic and Wegovy (semaglutide) causing users to lose up to 15% of their body fat on average.

page 22 from 40